UniProtKB/Swiss-Prot P60484 : Variant p.Tyr68His
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Gene: PTEN
Feedback ?
Variant information
Variant position:
68
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Tyrosine (Y) to Histidine (H) at position 68 (Y68H, p.Tyr68His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and aromatic (Y) to medium size and polar (H)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In CWS1; loss of phosphatase activity towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to bind phospholipid membranes.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
68
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
403
The length of the canonical sequence.
Location on the sequence:
NNIDDVVRFLDSKHKNHYKI
Y NLCAERHYDTAKFNCRVAQY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human NNIDDVVRFLDSKH-KNHYKIY NLCAERH-YDTAKFNCRVAQY
NNIDDVVRFLDSKH-KNHYKIY NLCAERH-YDTAKFNCRVA
Mouse NNIDDVVRFLDSKH-KNHYKIY NLCAERH-YDTAKFNCRVA
Rat NNIDDVVRFLDSKH-KNHYKIY NLCAERH-YDTAKFNCRVA
Xenopus laevis NNIDDVVRFLDSKH-KNHYKIY NLCAERH-YDTNKFSCRVA
Caenorhabditis elegans NSKVQTQQFLTRRHGKGNVKVF NLRGGYY-YDADNFDGNVI
Slime mold NPMKDVQRFLDQYH-KDHFKVY NLCSERV-YDHSKFYGRVG
Fission yeast NDELDVFKYLTTQL-KDNWILL NLCAEETVYHLELFKPNVI
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 403
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Domain
14 – 185
Phosphatase tensin-type
Alternative sequence
55 – 70
RFLDSKHKNHYKIYNL -> S. In isoform 3.
Beta strand
65 – 73
Literature citations
The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1.
Tsou H.C.; Ping X.L.; Xie X.X.; Gruener A.C.; Zhang H.; Nini R.; Swisshelm K.; Sybert V.; Diamond T.M.; Sutphen R.; Peacocke M.;
Hum. Genet. 102:467-473(1998)
Cited for: VARIANTS CWS1 HIS-68 AND PRO-112;
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
Marsh D.J.; Kum J.B.; Lunetta K.L.; Bennett M.J.; Gorlin R.J.; Ahmed S.F.; Bodurtha J.; Crowe C.; Curtis M.A.; Dasouki M.; Dunn T.; Feit H.; Geraghty M.T.; Graham J.M. Jr.; Hodgson S.V.; Hunter A.; Korf B.R.; Manchester D.; Miesfeldt S.; Murday V.A.; Nathanson K.L.; Parisi M.; Pober B.; Romano C.; Tolmie J.L.; Trembath R.; Winter R.M.; Zackai E.H.; Zori R.T.; Weng L.-P.; Dahia P.L.M.; Eng C.;
Hum. Mol. Genet. 8:1461-1472(1999)
Cited for: VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246;
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
Han S.-Y.; Kato H.; Kato S.; Suzuki T.; Shibata H.; Ishii S.; Shiiba K.; Matsuno S.; Kanamaru R.; Ishioka C.;
Cancer Res. 60:3147-3151(2000)
Cited for: CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; GLY-369 AND ILE-401; CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347;
Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography.
Marsh D.J.; Theodosopoulos G.; Howell V.; Richardson A.-L.; Benn D.E.; Proos A.L.; Eng C.; Robinson B.G.;
Neoplasia 3:236-244(2001)
Cited for: VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.